Labcorp and Rush University System for Health enter into a partnership focused on laboratory, clinical trial and data service

Labcorp (NYSE: LH) has entered into a comprehensive partnership with Rush University System for Health (RUSH) to serve as the primary lab for Chicago-based hospitals and physicians in the RUSH network. RUSH will also operate as a site partner for clinical trials through Labcorp’s drug development business, Covance. Together, Labcorp’s diagnostics and drug development expertise, along with RUSH’s deep roots in integrated, academic medicine, will enable scientific innovations and new care options for the communities RUSH serves.

“Our partnership with RUSH is rooted in our shared mission to bring scientific research and innovation to serve our patients and communities,” said Amy Rhine-Pallas, senior vice president of Labcorp Diagnostics’ North Central Division. “We believe our combined expertise will lead to enhanced access to testing services for RUSH patients, new care options in clinical trials and novel insights for patient care from combined data assets. In fact, we already have six trials active and enrolling with an additional five studies in the startup phase.”

“Partnering with Labcorp on diagnostic testing and clinical trials will help us further our mission to improve the health of the individuals and diverse communities we serve through data and partnerships,” says Dr. Ranga Krishnan, chief executive officer of RUSH. “Labcorp has the scale, depth of services and expertise to maintain our high-quality care and focus on our patients while optimizing diagnostic laboratory testing and scientific innovations.”